Kristina M.L. Acri, née Lybecker

Associate Professor of Economics, Colorado College

Kristina M.L. Acri, née Lybecker, Senior Fellow at the Fraser Institute, is an Associate Professor of Economics at Colorado College in Colorado Springs. Her research focuses largely on issues related to intellectual property (IP) rights protection with a particular focus on pharmaceutical-related IP.

Prof. Lybecker's recent publications include an evaluation of Canada's IP protection for pharmaceutical products based on international best practices, as well as examinations of alternatives to the existing patent system and the balance between pharmaceutical patent protection and access to essential medicines. She has testified in more than a dozen U.S. states on the economics of pharmaceutical counterfeiting and at the recent Trans-Pacific Partnership trade negotiations on the economics of access to medicine. Prof. Lybecker has also worked with the U.S. Food and Drug Administration, the OECD, and the World Bank on issues of innovation and international trade.

She earned a B.A. from Macalester College and received her Ph.D. in Economics from the University of California, Berkeley.

Recent Research by Kristina M.L. Acri, née Lybecker

— Dec 13, 2018
Printer-friendly version
The Unintended Consequences of National Pharmacare Programs: The Experiences of Australia, New Zealand, and the UK

The Unintended Consequences of National Pharmacare Programs in Australia, New Zealand and the UK finds that publicly-funded pharmacare schemes—similar to what some policymakers in Canada are considering—in other developed countries have resulted in reduced access to new drugs for patients, drug shortages, higher taxes and less pharmaceutical innovation.

— Jul 20, 2018
Printer-friendly version
Implications of the proposed changes to Canada's pharmaceutical pricing regulations

Implications of the Proposed Changes to Canada’s Pharmaceutical Pricing Regulations finds that the federal government’s plan to lower the cost of patented pharmaceuticals in Canada through new regulations seriously risks limiting patient access to new innovative drugs. The is the first study in a series on pharmaceutical drug pricing policy reforms.

— Feb 8, 2018
Printer-friendly version
Pharmaceutical Counterfeiting: Endangering Public Health, Society, and the Economy

Pharmaceutical Counterfeiting: Endangering Public Health, Society, and the Economy finds that counterfeit pharmaceutical drugs pose a real risk to Canadians because they are showing up in brick-and-mortar pharmacies, not just on the street and online, and counterfeiting medicines in Canada could be worth up to $89 million a year.